Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

The first patient has been treated in a phase 1/2 clinical ... melanoma. PD-L1 is a cell surface receptor expressed on both tumour and regulatory immune cells and functions as a checkpoint to ...

The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...

Tharimmune (THAR) announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both ...